Ethosuximide
- TRADE NAMES: Emeside; Ethymal; Petnidan; Pyknolepsinum; Simatin; Zarondan; Zarontin (Pfizer)
- INDICATIONS: Absence (petit mal) seizures
- CLASS: Antiepileptic; succinimide
- HALF-LIFE: 50–60 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antipsychotics, Carbamazepine, Chloroquine, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Hydroxychloroquine, Isoniazid, Levomepromazine, Lisdexamfetamine, MAO inhibitors, Mefloquine, Nevirapine, Orlistat, Phenobarbital, Phenytoin, Primidone, Risperidone, SSRIs, St John's Wort, Tricyclic antidepressants, Valproic Acid, Zuclopenthixol
PREGNANCY CATEGORY: C
Cases of birth defects have been reported with ethosuximide
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
